Sign Up
OverviewAPI
Alpha Cognition Inc. provides a business update on its NDA filing for Alzheimer’s disease, commercialization strategy, and pipeline update. The company transitioned from clinical research to a pre-commercial entity, filed an NDA for ALPHA-1062, and plans to launch commercially in the LTC and Neurology segments. Alpha Cognition also introduced a new formulation for patients unable to swallow tablets and completed a $6.5 million private placement capital raise.

Ask a question